Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cordis To Enroll 400 Patients In SIRIUS Trial After Conditional IDE

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's Cordis unit announced plans to begin enrolling 400 of the 1,100 patients selected for its Rapamune-eluting coronary stent clinical trial in the U.S. immediately following conditional investigational device exemption approval by FDA on Feb. 5.

You may also be interested in...



Cook, Inc. Coated Stent IDE Clearance Follows J&J/Cordis By One Month

Cook, Inc.' s March 2 investigational device exemption clearance appears to have cut Johnson & Johnson's six to eight-month lead in bringing a drug-eluting stent to the U.S. market by at least half.

Cook, Inc. Coated Stent IDE Clearance Follows J&J/Cordis By One Month

Cook, Inc.' s March 2 investigational device exemption clearance appears to have cut Johnson & Johnson's six to eight-month lead in bringing a drug-eluting stent to the U.S. market by at least half.

Boston Scientific Hedges Bets In Drug-Coated Stents With Quanam Buy

Boston Scientific's expansion of its drug-coated coronary stent R&D program through acquisition of Quanam could accelerate its European market entry by up to six months, the firm says.

Related Content

UsernamePublicRestriction

Register

MT014462

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel